Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
65
Language
English
Published on
30/10/24
You may also be interested by these reports :
27/11/25
We have lowered our target price to reflect the business challenges outlined in the EPS section. Additionally, we have adjusted the peer-based ...
26/11/25
While Q2 sales slightly missed market expectations, Elekta’s Q2 profitability surpassed forecasts, despite tariff impacts and FX headwinds. Improved ...
14/11/25
Sonova reported decent H1 results, with sales aligning with the company-compiled consensus. However, normalised EBITA did not meet expectations due ...
13/11/25
The Q3 results were somewhat ahead of expectations, and the 2025 guidance was maintained this time, after two downgrades earlier this year. This, ...